Latest Insider Transactions at Travere Therapeutics, Inc. (TVTX)
This section provides a real-time view of insider transactions for Travere Therapeutics, Inc. (TVTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Travere Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Travere Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
815
-0.91%
|
$11,410
$14.65 P/Share
|
|
May 15
2025
|
Roy D. Baynes |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+14.77%
|
-
|
|
May 15
2025
|
Suzanne Louise Bruhn |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+18.44%
|
-
|
|
May 15
2025
|
Timothy Coughlin |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+10.48%
|
-
|
|
May 15
2025
|
Gary A Lyons |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+10.16%
|
-
|
|
May 15
2025
|
Jeffrey A Meckler |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+6.91%
|
-
|
|
May 15
2025
|
John A Orwin |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+15.52%
|
-
|
|
May 15
2025
|
Sandra Poole |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+17.81%
|
-
|
|
May 15
2025
|
Ron Squarer |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+15.52%
|
-
|
|
May 15
2025
|
Brinkley Ruth Williams |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+20.16%
|
-
|
|
May 05
2025
|
Elizabeth E Reed Chief Legal Officer and GC |
SELL
Open market or private sale
|
Direct |
4,920
-5.21%
|
$103,320
$21.05 P/Share
|
|
May 05
2025
|
William E. Rote Chief Research Officer |
SELL
Open market or private sale
|
Direct |
3,198
-3.09%
|
$67,158
$21.05 P/Share
|
|
May 05
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,771
-1.36%
|
$37,191
$21.05 P/Share
|
|
May 05
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
18,924
-4.32%
|
$397,404
$21.05 P/Share
|
|
May 05
2025
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,784
-1.88%
|
$37,464
$21.05 P/Share
|
|
May 02
2025
|
Elizabeth E Reed Chief Legal Officer and GC |
BUY
Exercise of conversion of derivative security
|
Direct |
4,920
+4.95%
|
-
|
|
May 02
2025
|
William E. Rote Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,920
+4.54%
|
-
|
|
May 02
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,920
+3.65%
|
-
|
|
May 02
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,924
+4.14%
|
-
|
|
May 02
2025
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,920
+4.93%
|
-
|
|
Apr 11
2025
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
48
-0.05%
|
$624
$13.14 P/Share
|
|
Feb 12
2025
|
William E. Rote Chief Research Officer |
SELL
Open market or private sale
|
Direct |
5,200
-5.01%
|
$119,600
$23.53 P/Share
|
|
Feb 12
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,568
-2.01%
|
$59,064
$23.53 P/Share
|
|
Feb 12
2025
|
Elizabeth E Reed Chief Legal Officer and GC |
SELL
Open market or private sale
|
Direct |
8,000
-8.21%
|
$184,000
$23.53 P/Share
|
|
Feb 12
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,568
-2.79%
|
$59,064
$23.53 P/Share
|
|
Feb 11
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,074
-2.35%
|
$76,850
$25.0 P/Share
|
|
Feb 11
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
54,244
-14.86%
|
$1,356,100
$25.0 P/Share
|
|
Feb 11
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+12.97%
|
$720,000
$16.77 P/Share
|
|
Feb 11
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
11,375
-2.64%
|
$273,000
$24.04 P/Share
|
|
Feb 10
2025
|
William E. Rote Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+7.16%
|
-
|
|
Feb 10
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+5.77%
|
-
|
|
Feb 10
2025
|
Elizabeth E Reed Chief Legal Officer and GC |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+7.58%
|
-
|
|
Feb 10
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+7.99%
|
-
|
|
Feb 06
2025
|
Roy D. Baynes |
SELL
Open market or private sale
|
Direct |
10,000
-24.39%
|
$220,000
$22.0 P/Share
|
|
Feb 06
2025
|
Roy D. Baynes |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+19.61%
|
$170,000
$17.44 P/Share
|
|
Feb 04
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,066
-1.25%
|
$21,320
$20.11 P/Share
|
|
Feb 03
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
3,348
-5.0%
|
$66,960
$20.12 P/Share
|
|
Feb 03
2025
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,192
-5.45%
|
$103,840
$20.12 P/Share
|
|
Feb 03
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,166
-4.04%
|
$103,320
$20.12 P/Share
|
|
Feb 03
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,207
-4.7%
|
$84,140
$20.12 P/Share
|
|
Feb 03
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
50,691
-10.53%
|
$1,013,820
$20.21 P/Share
|
|
Feb 03
2025
|
Elizabeth E Reed Chief Legal Officer and GC |
SELL
Open market or private sale
|
Direct |
8,951
-9.09%
|
$170,069
$19.78 P/Share
|
|
Feb 03
2025
|
William E. Rote Chief Research Officer |
SELL
Open market or private sale
|
Direct |
8,951
-8.55%
|
$170,069
$19.78 P/Share
|
|
Jan 31
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,000
+16.25%
|
-
|
|
Jan 31
2025
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
21,500
+18.42%
|
-
|
|
Jan 31
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
21,500
+14.39%
|
-
|
|
Jan 31
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+25.12%
|
-
|
|
Jan 31
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
130,000
+21.27%
|
-
|
|
Jan 31
2025
|
Elizabeth E Reed Chief Legal Officer and GC |
BUY
Grant, award, or other acquisition
|
Direct |
21,500
+17.93%
|
-
|
|
Jan 31
2025
|
William E. Rote Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,500
+17.04%
|
-
|